CJC-1295 won't be found on pharmacy shelves in Fengo or virtually any local market — it's a research-grade peptide supplied via a dedicated online market. This matters because CJC-1295 quality differs enormously across the market — from verified research-grade material to mislabeled or underdosed compounds — and the vendor is the entire quality system. What reliably differentiates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety documentation. The sections below cover what Fengo researchers need to know about sourcing, verifying, and handling CJC-1295 for research purposes.
What Studies Say About CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Fengo comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
CJC-1295 Purchasing Guide
Before assessing any particular supplier, establish a quality benchmark — so you can tell whether a COA is complete and credible. Mass spectrometry in the COA establishes that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone does not confirm what the compound actually is. Negative indicators in CJC-1295 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that lack endotoxin data. The powdered lyophilised form of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations lose activity within weeks.
Order CJC-1295 — ships to Fengo
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and small-scale human observations. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — providing 25mcg per unit measured on a 100-unit syringe. Quality CJC-1295 sourcing directly determines safety outcomes — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that verified-quality sourcing directly prevents. Researchers running multi-compound protocols with CJC-1295 should check the research literature for any reported interactions before beginning combination research.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
